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Protein–cisplatin interactions lie at the heart of both the effectiveness of cisplatin as a
therapeutic agent and side effects associated with cisplatin treatment. Because a greater
understanding of the protein–cisplatin interactions at the molecular level can inform the
design of cisplatin-like agents for future use, mass spectrometric determination of the binding
site of cisplatin on a model protein, cytochrome c, was undertaken in this paper. The
monoadduct cytochrome c–Pt(NH3)2(H2O) is found to be the primary adduct produced by the
cytochrome c–cisplatin interactions under native conditions. To locate the primary binding site
of cisplatin, both free cytochrome c and the cytochrome c adducts underwent trypsin digestion,
followed by Fourier transform mass spectrometry (FT-MS) to identify unique fragments in the
adduct digest. Four such fragments were found in the adduct digest. Tandem mass spectrom-
etry (MS/MS and MS3 indicates that two fragments are Pt(NH3)2(H2O) bound peptides
(Gly56-Glu104 and Asn54-Glu104) with one water associated at the peptide bond Lys79
Met80, and the other two fragments are heme containing peptides (acety1-Gly1-Lys53 and
acety1-Gly1-Lys55). The product-ion spectra of the four fragments reveal that Met65 is the primary
binding site of cisplatin on cytochrome c. (J Am Soc Mass Spectrom 2009, 20, 1141–1147) © 2009
American Society for Mass SpectrometryCisplatin is effective in the treatment of variouscancers, particularly testicular and ovarian can-cers [1, 2]. In the body, cisplatin interacts with
DNA and thereby induces apoptosis in tumor cells [3,
4]. Because blood plasma proteins are good nucleo-
philes for cisplatin, they play an important role in
transporting cisplatin to the tumor cells [5]. Unfortu-
nately, some blood plasma protein–cisplatin binding is
irreversible, which not only renders cisplatin inactive
but also allows it to accumulate in tissues and induce
side effects [6, 7]. Exploration of protein–platinum met-
allodrug interactions provides insight into both the
transportation role of the blood plasma proteins that
enables therapeutic use and the irreversible binding
that induces side effects. This knowledge can be em-
ployed in the design of new therapeutic agents with
increased effectiveness and reduced side effects.
Several analytical techniques have been applied to
characterize cisplatin binding sites on model proteins.
Nuclear magnetic resonance spectroscopy (NMR) was
employed to locate the binding sites of cisplatin on
human serum albumin [8] and cytochrome c [9]. X-ray
crystallography elucidated the crystal structures of super-
oxide dismutase–cisplatin adducts [10] and lysozyme–
cisplatin adducts [11]. Electrospray ionization mass
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doi:10.1016/j.jasms.2009.02.013spectrometry (ESI-MS) [12, 13] coupled with the devel-
opment of technologies for determining protein post-
translational modifications [14] enabled characteriza-
tion of protein–Pt metallodrug interactions.
Gibson’s group first reported the studies of the
ubiquitin–cisplatin interactions using ESI-MS [15, 16].
Subsequently, the binding site of cisplatin on transferrin
was determined by liquid chromatography tandem
mass spectrometry (LC-MS/MS), providing the basis
for molecular modeling of the transferrin–cisplatin in-
teractions [17, 18]. In addition, the performances of
matrix-assisted laser desorption/ionization mass spec-
trometry (MALDI-MS) and ESI-MS were compared for
the study of the ubiquitin-Pt metallodrug interactions
[19]. More recently, Dyson and his coworkers [20]
reported a rapid top-down approach to determine the
binding sites of Pt metallodrugs on ubiquitin. Clearly,
mass spectrometry has proven to be a powerful tech-
nique for the study of the protein–Pt metallodrug
interactions.
Cytochrome c is a small, well-characterized protein
containing several potential binding sites for Pt metal-
lodrugs including methionines and histidines [21]. Like
ubiquitin, cytochrome c is a common model protein that
has been used to study the protein–Pt metallodrug
interactions by ESI-MS and MS/MS. LC-MS/MS exper-
iments, described in the literature [22], enabled the
determination of the binding sites of carboplatin on
cytochrome c. Although Casini et al. [23] reported the
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ESI-MS, they did not determine the binding site of
cisplatin on cytochrome c. Recently, Casini et al. [24]
reported a comprehensive study of the interactions of Pt
(II) iminoethers with cytochrome c including the deter-
mination of the primary binding site of Pt (II) imi-
noethers on cytochrome c based on ESI-MS and NMR.
Assigning the location of a protein’s binding site(s)
for Pt metallodrugs is essential to better understanding
the protein–Pt metallodrug interactions. This research
describes direct determination of the binding site(s) of
cisplatin on cytochrome c via Fourier transform mass
spectrometry (FT-MS) [25] and tandem mass spectrom-
etry (MSn). The high-resolution and high mass accuracy
of FT-MS enable identification of different fragments in
the adduct digest from those in the free cytochrome c
digest without need for a sample purification step. MSn
analyses of the unique fragments in the adduct digest
provide their structural information and enable the
determination of the binding site(s) of cisplatin based
on the mass shift of b ions or y ions of the peptides in
the Pt-compound containing fragments [26], revealed
by broader isotope distributions of some product ions
in their product-ion spectra [18].
Experimental
Materials
Horse heart cytochrome c, cisplatin, ammonium acetate
(NH4OAc), and ammonium bicarbonate were pur-
chased from Sigma (St. Louis, MO). Sequencing grade
modified trypsin, methanol (HPLC grade), and acetic
acid (HAc) (analytical grade) were obtained from Fisher
Scientific (Pittsburgh, PA). All chemicals were pur-
chased in highest purity available and used directly
without further purification. Deionized water was used
throughout the experiments.
Preparation of the Cytochrome c–Cisplatin Adducts
One hundred uM cytochrome c was reacted with cis-
platin at different molar ratios (cytochrome c:cisplatin
1:4, 1:8, 1:12, and 1:16) under native conditions in 5 mM
NH4OAc aqueous solution (pH 6.8) at 37 °C for differ-
ent times to investigate the formation of the cytochrome
c–cisplatin adducts by ESI-MS. The cytochrome c–
cisplatin adducts used in protein digestion were pre-
pared by reacting 100 uM cytochrome cwith cisplatin at
1:16 cytochrome c:cisplatin molar ratio at pH 6.8, 37 °C
for 24 h. Before ESI-MS, the cytochrome c solutions
were diluted to 100 nM with a 30% MeOH-5 mM
NH4OAc solution. Because the peak area of each species
in the ESI-MS spectrum is linearly related to its concen-
tration in solution at low concentrations [27], it is used
to estimate the percentage of each cytochrome c species
in the solution by calculating the ratio of the peak area
of the cytochrome c species to the sum of the peak areas
of all the cytochrome c species, under the assumptionthat there is no mass discrimination during the ESI-MS
analyses of all the cytochrome c species [28].
Protein Digestion
The cytochrome c–cisplatin adducts in the 1:16 cyto-
chrome c:cisplatin mixture were diluted to 20 uM with
50 mM NH4HCO3 (pH 7.8) and then subjected to
trypsin digestion at a protein to enzyme ratio of 50:1
(wt/wt) at 37 °C for 70 min. As a control, 20 uM free
cytochrome c was digested under the same conditions.
Before ESI-MS analysis, the digest solution was diluted
to 5 uM with a 50% MeOH-0.1% HAc buffer.
ESI-MS Analyses of the Cytochrome c Adducts
ESI-MS analyses of free cytochrome c and the cyto-
chrome c–cisplatin adducts were carried out on a
quadrupole ion trap mass spectrometer coupled with a
standard electrospray ionization source (Finnigan LCQ,
San Jose, CA). The heated metal capillary was main-
tained at 200 °C. The spray voltage was set to 4.5 kV.
Nitrogen was used as the sheath gas and its flow rate
was 30 units/min. The capillary voltage and the tube
lens voltage were held at 35 and 10 V, respectively. The
cytochrome c solutions were introduced by direct infu-
sion with a flow rate of 3 uL/min. Ion optics were tuned
at 1766 m/z. A mass range of 1500–2000 m/z was used to
collect ESI-MS spectra. The ESI-MS spectra were decon-
voluted using MagTran software [29]. OriginPro 8
(OriginLab Corporation, Northampton, MA) was used
to plot the data obtained in preparation of the cyto-
chrome c—cisplatin adducts.
FT-MS, MS/MS, and MS3 Analyses
FT-MS, MS/MS, and MS3 analyses of the cytochrome c
digests were carried out on a Thermo Finnigan LTQ-FT
system equipped with an Ion Max ion source (San Jose,
CA). The operating conditions of the ESI source were
mentioned above. The digests were introduced by di-
rect infusion at 3 uL/min. Ion optics were tuned for the
ions of interest. FT-MS analyses of the free cytochrome
c digest and the adduct digest in a mass range of
500–2000 m/z were performed to identify unique frag-
ments in the adduct digest. Those fragments appearing
uniquely in the FT-MS spectrum of the adduct digest
were subjected to MS/MS and MS3 in the linear ion
trap. The isolation width was set to 5 m/z. He was used
as the collision gas. The amplitude of normalization
collision energy (NCE) was 30% in MS/MS and MS3.
Before collision induced dissociation (CID), the ions of
interest were accumulated for 150 to 500 ms to increase
ion intensity. The isotope distributions of product ions
were obtained by zoom scan. All product spectra were
recorded in a full mass range during the MS/MS and
MS3 analyses of the digests. The product spectra were
replotted and labeled in Origin 6.0 (OriginLab Corpo-
ration, Northampton, MA). ExPASy Proteomics Server
1143J Am Soc Mass Spectrom 2009, 20, 1141–1147 DETERMINATION OF CISPLATIN ON CYTOCHROME c BY MSwas used to search the cytochrome c sequence and to
calculate the theoretical mass of the fragments in the
adduct digest and the product ions of the peptides
involved.
Results and Discussion
Preparation of the Cytochrome c–Cisplatin Adducts
The formation of the cytochrome c adducts in three
solutions, containing cytochrome c and cisplatin at
molar ratios of 1:4, 1:8, and 1:12, respectively, was
examined at different time intervals over 30 h to
monitor the adduct formation. Throughout these stud-
ies, 12,604.3 Da is the primary adduct ion observed in
the deconvoluted ESI-MS spectra. This signal is as-
signed as monoadduct cytochrome c-Pt(NH3)2(H2O)
because the formation of the adduct results in a mass
shift of 245.9 Da from free cytochrome c (measured
mass 12,358.4 Da), which is close to the theoretical
mass of Pt(NH3)2(H2O) (246.026 Da). No cytochrome
c–Pt(NH3)2Cl is detected, indicating that the side
chains of cytochrome c replace one water in hydro-
lyzed cisplatin Pt(NH3)2(H2O)2 yielding cytochrome
c–Pt(NH3)2(H2O) [19]. For clarity, the charge states of
the Pt compounds are omitted in this paper. The
formation of cytochrome c–Pt(NH3)2(H2O) is described
by eqs 1 and 2:
Pt(NH3)2Cl2 2H2O^Pt(NH3)2(H2O)2 2Cl (1)
cytcPt(NH3)2(H2O)2^cytcPt(NH3)2(H2O)H2O
(2)
Because the peak area of the monoadduct cytochrome
c–Pt(NH3)2H2O covers over 90% of the sum of the peak
areas of all the cytochrome c–cisplatin adducts in each
spectrum, the percentage of cytochrome c–Pt(NH3)2H2O
in the total cytochrome c of each solution is used to
represent the formed adducts. Figure 1 shows the
changes of the percentage of cytochrome c–Pt(NH3)2H2O
in three solutions over 30 h. Although more cyto-
chrome c–Pt(NH3)2H2O appears in the solution with a
higher cisplatin concentration, the trends of the for-
mation of cytochrome c–Pt(NH3)2H2O are similar in
the three solutions. The percentage of cytochrome
c–Pt(NH3)2(H2O) in all three solutions increases sharply
during the first 5 h, and then increases gradually until
21 h, after which it remains constant indicating the
attainment of equilibrium. In this research, 24 h is
used as the reaction time to prepare the cytochrome
c–cisplatin adducts for protein digestion.
Figure 2 shows the deconvoluted ESI-MS spectra,
obtained using a quadrupole ion trap, of free cyto-
chrome c and the cytochrome c–cisplatin adducts pre-
pared by reacting 100 uM of cytochrome cwith cisplatin
at different cytochrome c:cisplatin molar ratios (1:8,
1:12, and 1:16) under native conditions for 24 h. The
mass accuracy for these ion trap data is 2 Da. Threegroups of peaks are observed, arising from free cyto-
chrome c, the 1:1 cytochrome c:cisplatin adducts (mono-
adducts), and the 1:2 cytochrome c:cisplatin adducts
(diadducts), respectively. In all of these spectra, the
diadduct signal is extremely low, indicating that mono-
adducts are the major adducts. Besides the primary
monoadduct cytochrome c–Pt(NH3)2(H2O), the other
monoadducts are assigned as cytochrome c–Pt(NH3),
cytochrome c–Pt(NH3)2, cytochrome c–Na-Pt(NH3)2(H2O),
and cytochrome c–H2O-Na-Pt(NH3)2(H2O) correspond-
ing to the small peaks at 12,569.0, 12,586.2, 12,626.7, and
12,644.3 Da [30]. Because these spectra also indicate that
the largest amount of adducts are produced in the 1:16
cytochrome c–cisplatin solution, this solution is selected
for the preparation of the cytochrome c–cisplatin ad-
ducts for trypsin digestion in the following studies
conducted using an FT-MS system.
Determination of the Primary Binding Site of
Cisplatin on Cytochrome c
Protein digestion. MSn analyses of smaller fragments
arising from trypsin digestion of the cytochrome
c–cisplatin adducts provide information regarding the
adduct structure. Because the stable cytochrome c–
cisplatin adducts were obtained under native condi-
tions, trypsin digestion was performed under native
conditions to prevent dissociation of the Pt-compounds
from cytochrome c and cytochrome c fragments. A 50
mM NH4HCO3 aqueous solution (pH 7.8) held at 37 °C
was used for optimal conditions in trypsin digestion
[31]. Initially, free cytochrome c was digested under the
above conditions for 70 min to serve as the experimen-
tal control. FT-MS analysis of the free cytochrome c
digest indicates complete digestion (spectrum not
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Figure 1. The percentage of cytochrome c-Pt(NH3)2(H2O) in three
cytochrome c-cisplatin solutions: (filled triangle) 1:4 cytochrome
c:cisplatin; (filled square) 1:8 cytochrome c:cisplatin; (filled circle) 1:12
cytochrome c:cisplatin at different time intervals over 30 h.shown). Small peptides with low charge states from 1 to
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abundant signals in the FT-MS spectrum of the free
cytochrome c digest.
Under the same conditions, the adduct solution pre-
pared from 1:16 cytochrome c:cisplatin mixture was di-
gested. A detailed comparison of the FT-MS spectra of the
adduct digest and the free cytochrome c digest was carried
out to identify the new digest fragments in the adduct
digest. The FT-MS spectrum of the adduct digest is
displayed in Figure 3 (The FT-MS spectrum of the free
cytochrome c digest is provided as a Supplementary
Figure in the electronic version of this article). In Figure 3,
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Figure 2. Deconvoluted ESI-MS spectra of free cyt c and the cyt
c-cisplatin adducts obtained by incubating cyt c and cisplatin at
different molar ratios for 24 h under native conditions. The
assignment of individual peaks in the mass spectra: A – cyt c (12,358.4
Da); B – cyt c–H2O (12,377.3 Da); C – cyt c–(H2O)2 (12,394.6 Da); D – cyt
c–Pt(NH3) (12,569.0 Da); E – cyt c–Pt(NH3)2 (12,586.2 Da); F – cyt
c–Pt(NH3)2(H2O) (12,604.3 Da); G – cyt c–Na-Pt(NH3)2(H2O) (12,626.7
Da); H – cyt c–H2O-Na-Pt(NH3)2(H2O) (12,644.3 Da).Figure 3. The FT-MS spectruthe new fragments in the mass range over 1000 m/z with
high charges (4 to 6) suggest partial digestion of the
adducts. Such partial digestion of the adducts suggests
that cisplatin binding to cytochrome c decreases the ability
of trypsin to access the cleavable sites. Although extension
of the digestion time permits complete digestion, it also
leads to an increase in background arising from non-
specific cleavage. Therefore, the digestion time of the
cytochrome c adducts was 70 min, the same as the
digestion time of free cytochrome c.
Further MSn analyses of the new fragments observed
in the adduct digest indicate that these fragments
correspond to four multiply charged fragments listed in
Table 1, obtained by trypsin cleavage at two peptide
bonds in the adducts. Of the four fragments, two are
Pt(NH3)2(H2O)-containing peptides and the other two
are heme-containing peptides. The product-ion spectra
of these four fragments reveal the primary binding site
of cisplatin.
Determination of the Primary Binding Site from
Fragment No. 1 and Fragment No. 2
MS/MS and MS3 analyses indicate both 1507.7774 and
1206.4235 ions arise from fragment no. 1. Figure 4
shows the product-ion spectrum from MS/MS of the
1507.7774 ion, in which two abundant doubly charged
fragment ions 1456.27 and 1558.18 appear. The total
mass of the 1456.272 and 1558.182 ions is 6024.90 Da,
which has 2.21 Da mass difference from the mass of
the parent ion 1507.7774 (6027.11 Da), suggesting that
1507.7774 primarily fragments at one position during
CID to produce the 1456.272 and 1558.182 fragment
ions. MS3 analyses of both fragment ions provide addi-
tional structural information. MS3 analysis of the
1456.272 ion from the 1507.7774 ion, Figure 5, indi-m of the adduct digest.
1145J Am Soc Mass Spectrom 2009, 20, 1141–1147 DETERMINATION OF CISPLATIN ON CYTOCHROME c BY MScates that the 1456.272 ion corresponds to a peptide
with the sequence Met80-Glu104 (theoretical mass
2909.60 Da). The 1456.272 ion has a mass deviation of
0.93 Da from the theoretical mass of Met80-Glu104.
Met80-Glu104 is at the C terminus of the cytochrome c
sequence, suggesting that the 1456.272 and 1558.182
ions arise from the cleavage of the Lys79Met80 pep-
tide bond.
The broader isotope distribution of the ion envelope
at 1558.182 compared with that at 1456.272 in Figure
4 suggests 1558.182 corresponds to a Pt-compound
containing fragment. Because Pt(NH3)2(H2O) is the
primary Pt compound bound to cytochrome c, the
peptide mass of 1558.182 is estimated by subtracting
the mass of Pt(NH3)2(H2O) (246.03 Da) from the mass of
1558.182 (2868.33 Da). The estimated mass is very close
to the mass of the peptide Gly56-Lys79 (theoretical
mass 2867.48 Da) with a mass difference of 0.85 Da. The
peptide sequence of 1558.182 as Gly56-Lys79 is consis-
tent with the above result that 1558.182 is produced by
cleaving the peptide bond Lys79Met80 in fragment
no. 1. Some sequence ions of peptide Lys56-Met79 are
also observed in the MS3 analysis of 1507.7774 at
1558.182, Figure 6. Consequently, the fragmentation of
fragment no. 1 produces two peptide fragments, the
Pt(NH3)2(H2O) bound peptide Gly56-Lys79 and the
peptide Met80-Glu104. The formation of two peptide
fragments in gas-phase from fragment no. 1 suggests
that one water molecule is associated with the peptide
Figure 4. The product-ion spectrum of the MS
Table 1. Four new fragments in the FT-MS spectrum of the add
Fragments The fragments’ composition m
No. 1 Gly56-Glu104 H2O Pt(NH3)2(H2O) 1507.777
No. 2 Asn54-Glu104 H2O Pt(NH3)2(H2O) 1568.311
No. 3 Acety1-Gly1-Lys53Heme 1593.546
No. 4 Acetyl-Gly1-Lys55Heme 1654.077
*m is mass deviation of measured mass from calculated mass.product ions 1456.272, and 1558.182.bond Lys79Met80. The peptide bond Lys79Met80 is
not cleaved in trypsin digestion even after it is associ-
ated with one water molecule, suggesting the interac-
tions Pt(NH3)2(H2O) with the peptide Gly56-Glu104
results in a more stable Lys79Met80 peptide bond.
In Figure 6, 1531.642 is the primary product ion
produced by neutral loss of two H2O and one NH3
from the 1558.182 ion, indicating the peptide bonds
in the 1558.182 ion are hard to break due to the
Pt(NH3)2(H2O) binding. Most peaks are enlarged 20
times in Figure 6 to display the sequence ions for
the peptide Gly56-Lys79 and the Pt-compound contain-
ing fragment ions (1383.45, 1419.36, and 1952.82).
The strong intensity of y14
 (1679.82) suggests that the
peptide bond Met65Glu66 readily fragments. The
calculated mass of the complementary ion of y14
 is
1436.54 Da, which is close to the molecular mass of
[b10  Pt(NH3)2(H2O)]
 (theoretical mass1435.62 Da).
However, the 1383.45 and 1419.36 ions are observed
and assigned as the Pt-compound containing b10
 ions
because neutral loss dominates during fragmenting the
1558.182 ion, indicated by the primary fragment ion
1531.642 in Figure 6. Based on the assignments of the
Pt-compound containing fragment ions, the Pt com-
pounds bind to one of the amino acid residues of the
b10
 ion (Gly56-Met65), in which Met65 has highest
affinity for the Pt(II) compounds. Therefore, Met65 is
the most probable binding site for Pt(NH3)2(H2O).
Met65 is located in the middle of the fragment Gly56-
analysis of 1507.7774 and zoom scans of the
igest identified by MS/MS and MS3 analyses
the fragments
Calculated
mass (Da) Measured mass (Da)
206.4235 6023.109 6027.112 m*  4.003
254.8505 6265.247 6269.247 m  4.000
275.0375 1062.6976 6369.124 6370.184 m  1.060
323.4635 1102.8876 6611.262 6611.982 m  0.720/MSuct d
/z of
4 1
4 1
4 1
4 1
1146 ZHAO AND KING J Am Soc Mass Spectrom 2009, 20, 1141–1147Lys79 and the tight interaction between Pt(NH3)2(H2O)
and Met65, contributes to strong peptide bonds in the
MS3 analysis of 1507.7774 at 1558.182.
The MS/MS and MS3 analyses of fragment no. 2
indicate that fragment no. 2 is the Pt(NH3)2(H2O) bound
Asn54-Glu104 and Met65 is the Pt(NH3)2(H2O) binding
site on the peptide Asn54-Glu104 (data not shown).
Identification of Fragment No. 3 and Fragment
No. 4
Fragment no. 3 is represented by three ions 1593.5464,
1275.0375, 1062.6976, and fragment no. 4 is also
observed as three ions 1654.0774, 1323.4635, 1102.8876,
in Figure 3. A 617.27 m/z ion is observed in the product
spectra of the MS/MS analyses of fragment no. 3 and
fragment no. 4, indicating both fragments contain the
heme group. Comparison of the product spectra of the
MS/MS analyses of the most abundant ions, 1275.0375
for fragment no. 3 and 1323.4635 for fragment no. 4
(spectra not shown), reveals similar fragmentation pat-
terns and several common fragment ions, suggesting
that fragment no. 3 and fragment no. 4 are of similar
structure. Further spectral analysis indicates that frag-
ment no. 3 is identified as a heme containing peptide,
the sequence of which is Acetyl-Gly1-Lys53, produced
by cleaving Lys53Asn54 in trypsin digestion. Frag-
ment no. 4 is a heme bound peptide, acetyl-Gly1-Lys55,
produced by cleaving Lys55Gly56 in trypsin diges-
tion. Therefore, fragment no. 3 is complementary to
fragment no. 2 and fragment no. 4 is complementary to
fragment no. 1 according to the cytochrome c sequence,
suggesting the cleavage mainly occurred at two posi-
tions (Lys53Asn54 and Lys55Gly56) in trypsin di-
gestion of the cytochrome c adduct. The results of the
MSn analyses of the four fragments indicate that Met65
is the primary binding site of cisplatin on cytochrome c,
Figure 5. The product-ion spectrum of the MS3 analysis of
1507.7774 at 1456.272: the peptide sequence of 1456.272:
(Met80-Glu104) MIFAGIKKKTEREDLIAYLKKATNE.which is consistent with the previously reported results
from NMR [9].
Conclusions
This research illustrates a mass spectrometric method
for the direct determination of the primary binding site
of cisplatin on cytochrome c. ESI-MS data reveal that the
cytochrome c–t(NH3)2(H2O) monoadduct is the primary
adduct produced by the cytochrome c–cisplatin inter-
actions under native conditions in 30 h. Four new
fragments appear in the adduct digest compared with
the free cytochrome c digest. The complete identifica-
tion of these four fragments suggests that the cyto-
chrome c adducts are cleaved mainly at two positions
Lys53Asn54 and Lys55Gly56 by trypsin. These data
support the assignment of Met65 as the primary bind-
ing site of cisplatin on cytochrome c. Therefore, the
monoadduct cytochrome c–Pt(NH3)2(H2O) arises from
covalent interactions between Pt(NH3)2(H2O) and Met65
in cytochrome c. The high specificity of this MS method
enables direct determination of the primary cisplatin
binding site without need for additional sample purifi-
cation. The successful identification implies that this
mass spectrometric approach based on FT-MS and MSn
can be useful in the exploration of the binding site(s) of
the Pt metallodrugs on other proteins.
Acknowledgments
The authors gratefully acknowledge funding from the NSF EPSCoR
program that provided the LTQ-FT mass spectrometer employed
in these studies. The authors appreciate Dr. Zhongqi Zhang for
kindly providing the MagTran software used in the ESI-MS
spectral deconvolution. They thank Brent Robert Reschke for help
in conducting the FTMS experiments and Megan DeJesus for
Figure 6. The product-ion spectrum of the MS3 analysis of
1507.7774 at 1558.182: the peptide sequence of 1558.182:
(Gly56-Lys79) GITWKEETLMEYLENPKKYI PGTK.valuable editorial suggestions on the manuscript.
1147J Am Soc Mass Spectrom 2009, 20, 1141–1147 DETERMINATION OF CISPLATIN ON CYTOCHROME c BY MSAppendix
Supplementary Material
Supplementary material associated with this article
may be found in the online version at doi:10.1016/
j.jasms.2009.02.013.
References
1. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of
cisplatin–DNA adducts. Chem. Rev. 1999, 99, 2467–2498.
2. Lippert, B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer
Drug; Wiley-VCH, New York, 1999.
3. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metast.
Rev. 1992, 11, 121–139.
4. Hurley, L. H.; Boyd, F L. DNA as a target for drug action. Trends
Pharmacol. Sci. 1988, 9, 402–407.
5. DeConti, R. C.; Toftness, B. R.; Lange, R. C.; Creasey, W. A. Clinical and
pharmacological studies with cis-diamminedichloroplatinum (II). Can-
cer Res. 1973, 33, 1310–1315.
6. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K.
Interactions of antitumor metallodrugs with serum proteins: Advances
in characterization using modern analytical methodology. Chem. Rev.
2006, 106, 2224–2248.
7. Appleton, T. G. Donor atom preferences in complexes of platinum and
palladium with amino acids and related molecules. Coord. Chem. Rev.
1997, 166, 313–359.
8. Ivanov, A. I.; Christodoulou, J.; Parkinson, J. A.; Barnham, K. J.; Tucker,
A.; Woodrow, J.; Sadler, P. J. Cisplatin binding sites on human albumin.
J. Biol. Chem. 1998, 273, 14721–14730.
9. Jiang, L.; Chen, Y.; Tang, G.; Tang, W. Studies on the interaction
between cytochrome c and cis-PtCl2(NH3)2. J. Inorg. Biochem. 1997, 65,
73–77.
10. Calderone, V.; Casini, A.; Mangani, S.; Messori, L.; Orioli, P. L. Struc-
tural investigation of cisplatin–protein interactions: Selective platina-
tion of His19 in a cuprozinc superoxide dismutase. Angew. Chem. Int. Ed.
2006, 45, 1267–1269.
11. Casini, A.; Mastrobuoni, G.; Temperini, C.; Gabbiani, C.; Francese, S.;
Moneti, G.; Supuran, C. T.; Scozzafava, A.; Messori, L. ESI mass
spectrometry and X-ray diffraction studies of adducts between antican-
cer platinum drugs and hen egg white lysozyme. Chem. Commun. 2007,
2, 156–158.
12. Heck, A. J. R.; Van Den Heuvel, R. H. H. Investigation of intact protein
complexes by mass spectrometry.Mass Spectrom. Rev. 2004, 23, 368–389.
13. Loo, J. A. Studying noncovalent protein complexes by electrospray
ionization mass spectrometry. Mass Spectrom. Rev. 1997, 16, 1–23.
14. Carr, S. A.; Annan, R. S.; Huddleston, M. J. Mapping post-translational
modifications of proteins by MS-based selective detection: application
to phosphoproteomics. Methods Enzymol. 2005, 405, 82–115.15. Gibson, D.; Costello, C. E. A mass spectral study of the binding of the
anticancer drug cisplatin to ubiquitin. Eur. Mass Spectrom. 1999, 5,
501–510.
16. Peleg-Shulman, T.; Gibson, D. Cisplatin–protein adducts are efficiently
removed by glutathione but not by 5=-guanosine monophosphate. JACS
2001, 123, 3171–3172.
17. Allardyce, C. S.; Dyson, P. J.; Coffey, J.; Johnson, N. Determination of
drug binding sites to proteins by electrospray ionization mass spec-
trometry: The interaction of cisplatin with transferrin. Rapid Commun.
Mass Spectrom. 2002, 16, 933–935.
18. Khalaila, I.; Allardyce, C. S.; Verma, C. S.; Dyson, P. J. A mass
spectrometric and molecular modelling study of cisplatin binding to
transferrin. Chembiochemistry 2005, 6, 1788–1795.
19. Hartinger, C. G.; Ang, W. H.; Casini, A.; Messori, L.; Keppler, B. K.;
Dyson, P. J. Mass spectrometric analysis of ubiquitin–platinum interac-
tions of leading anticancer drugs: MALDI versus ESI. J. Anal. At.
Spectrom. 2007, 22, 960–967.
20. Hartinger, C. G.; Tsybin, Y. O.; Fuchser, J.; Dyson, P. J. Characterization
of platinum anticancer drug protein-binding sites using a top-down
mass spectrometric approach. Inorg. Chem. 2008, 47, 17–19.
21. Bushnell, G.; Louie, G.; Brayer, G. High-resolution three-dimensional
structure of horse heart cytochrome c. Mol. Biol. 1990, 214, 585–595.
22. Yang, G.; Miao, R.; Jin, C.; Mei, Y.; Tang, H.; Hong, J.; Guo, Z.; Zhu, L.
Determination of binding sites in carboplatin-bound cytochrome c
using electrospray ionization mass spectrometry and tandem mass
spectrometry. J. Mass. Spectrom. 2005, 40, 1005–1016.
23. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Moneti, G.;
Pieraccini, G. Exploring metallodrug-protein interactions by ESI mass
spectrometry: The reaction of anticancer platinum drugs with horse
heart cytochrome c. Chem. Med. Chem. 2006, 1, 413–417.
24. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R. Z.; Intini, F. P.;
Arnesano, F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L. Insights
into the molecular mechanisms of protein platination from a case study:
The reaction of anticancer platinum(II) iminoethers with horse heart
cytochrome c. Biochemistry 2007, 46, 12220–12230.
25. Marshall, A. G.; Hendrickson, C. L.; Jackson, G. S. Fourier transform ion
cyclotron resonance mass spectrometry: A primer. Mass Spectrom. Rev.
1998, 17, 1–35.
26. Medzihradszky, K. F. Peptide sequence analysis.Methods Enzymol. 2005,
402, 209–244.
27. Tang, L.; Kebarle, P. Dependence of ion intensity in electrospray mass
spectrometry on the concentration of the analytes in the electrosprayed
solution. Anal. Chem. 1993, 65, 3654–3668.
28. Gabelica, V.; Galic, N.; Rosu, F.; Houssier, C.; Pauw, E. D. Influence of
response factors on determining equilibrium association constants of
noncovalent complexes by electrospray ionization mass spectrometry. J.
Mass Spectrom. 2003, 38, 491–501.
29. Zhang, Z.; Marshall, A. G. A universal algorithm for fast and automated
charge state deconvolution of electrospray mass-to-charge ratio spectra.
J. Am. Soc. Mass Spectrom. 1998, 9, 225–233.
30. Qi, P. X.; Urbauer, J. L.; Fuentes, E. J.; Leopold, M. F.; Wand, A. J.
Structural water in oxidized and reduced horse heart cytochrome c.
Nature Struct. Biol. 1994, 1, 378–382.31. Medzihradszky, K. F. In-solution digestion of proteins for mass spec-
trometry. Methods Enzymol. 2005, 405, 50–65.
